Dendritic Cells Transfected with a DNA Construct Encoding Tumour‐associated Antigen Epitopes Induce a Cytotoxic Immune Response Against Autologous Tumour Cells in a Culture of Mononuclear Cells from Colorectal Cancer Patients
Authors:
- Ekaterina Vladimirovna KulikovaEKEkaterina Vladimirovna Kulikova
- Vasily Vasilevich KurilinVKVasily Vasilevich Kurilin
- Julia Aleksandrovna ShevchenkoJSJulia Aleksandrovna Shevchenko
- Uljana Aleksandrovna BoyarskikhUBUljana Aleksandrovna Boyarskikh
- Maxim Leonidivich FilipenkoMaxim Leonidivich Filipenko
- Andrey Viktorovich SokolovASAndrey Viktorovich Sokolov
- Sergey Vitalievich SennikovSSSergey Vitalievich Sennikov
Open Access
- 3 July 2015
- journal article
- Published by Wiley in Scandinavian Journal of Immunology
- Vol. 82 (2) , 110-117
Abstract
Significant effort has been devoted to developing effective cancer vaccines based on dendritic cells (DCs) loaded with various tumour antigens, including DNA constructs that carry sequences of tumour‐associated antigens (TAAs). Such vaccines efficiently and selectively activate the T cell immune response. In this study, we describe a method to induce an antitumour immune response in mononuclear cell (MNC) cultures from colorectal cancer patients using DNA‐transfected DCs encoding TAA epitopes of carcinoembryonic antigen, epithelial cell adhesion molecule and mucin 4. DCs were obtained from peripheral blood monocytes of colorectal cancer patients. Magnetic‐assisted transfection was used to deliver the genetic constructs to DCs. To assess the potency of the immune response, the antitumour cytotoxic response was assessed by lymphocyte intracellular perforin and the MNC cytotoxic activity against autologous tumour cells. We showed that polyepitope DNA‐transfected DCs enhanced MNC antitumour activity, increasing tumour cell death and the percentage of perforin‐positive lymphocytes. In addition, DNA‐transfected DCs elicited a cytotoxic response that was as efficient as that of tumour lysate‐loaded DCs. Taken together, the data suggest that it is feasible to induce an antitumour immune response in colorectal MNCs using transfected DCs. Thus, the DNA construct reported in this study may potentially be used in therapeutic and prophylactic DC‐based vaccines.Keywords
Funding Information
- The Ministry of Education and Science of the Russian Federation (RFMEFI60714X0043)
This publication has 34 references indexed in Scilit:
- Engineering Dendritic Cells to Enhance Cancer ImmunotherapyMolecular Therapy, 2011
- TAA Polyepitope DNA-Based Vaccines: A Potential Tool for Cancer TherapyJournal of Biomedicine and Biotechnology, 2010
- Immunity, Inflammation, and CancerCell, 2010
- CD4+ T Cells Regulate Pulmonary Metastasis of Mammary Carcinomas by Enhancing Protumor Properties of MacrophagesCancer Cell, 2009
- Characterization of Genetically Modified T-Cell Receptors that Recognize the CEA:691-699 Peptide in the Context of HLA-A2.1 on Human Colorectal Cancer CellsClinical Cancer Research, 2008
- A Polyepitope DNA Vaccine Targeted to Her-2/ErbB-2 Elicits a Broad Range of Human and Murine CTL Effectors to Protect against Tumor ChallengeCancer Research, 2007
- Induction of Mucosal and Systemic Immune Responses against Human Carcinoembryonic Antigen by an Oral VaccineCancer Research, 2005
- Dendritic Cells Transduced with Tumor-Associated Antigen Gene Elicit Potent Therapeutic Antitumor Immunity: Comparison with Immunodominant Peptide-Pulsed DCsOncology, 2005
- Vaccination with Ep-CAM Protein or Anti-Idiotypic Antibody Induces Th1-Biased Response against MHC Class I- and II-Restricted Ep-CAM Epitopes in Colorectal Carcinoma PatientsClinical Cancer Research, 2004
- Generation of Carcinoembryonic Antigen (CEA)-Specific T-Cell Responses in HLA-A*0201 and HLA-A*2402 Late-Stage Colorectal Cancer Patients after Vaccination with Dendritic Cells Loaded with CEA PeptidesClinical Cancer Research, 2004